PHILADELPHIA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against  James Hardie Industries plc (NYSE: JHX) (“James Hardie” or the “Company”) on behalf of investors who purchased James Hardie common stock and American Depositary Shares during the period of May 20, 2025 through August 18, 2025 (the “Class Period”). Investor Deadline: Investors who purchased James Hardie securities during the Class Period may, no later than December 23, 20 ...

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc, alleging significant accounting irregularities and misleading disclosures that resulted in inflated profits and concealed losses [1][3]. Summary by Sections Lawsuit Announcement - Berger Montague PC has announced a class action lawsuit on behalf of investors who purchased Marex shares from May 16, 2024, to August 5, 2025 [1][2]. Allegations - The lawsuit claims that Marex engaged in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions to hide losses and inflate profits [3][4]. - Specific allegations include a fabricated $17 million receivable, a subsidiary's profits inflated by 150%, and a significant discrepancy in asset valuation, where an asset valued at $14.9 million was sold for only $2.5 million weeks later [4]. Financial Impact - Following the release of the NINGI Research report, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31, indicating substantial investor losses [5].

Accessibility StatementSkip Navigation PHILADELPHIA, Dec. 1, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Cepton, Inc. (NASDAQ: CPTN) ("Cepton" or the "Company") on behalf of investors who purchased or sold Cepton shares during the period of July 29, 2024 through January 6, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or sold Cepton securities during the Class Period may, no later than December 8, 2025, seek to be ...

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly making false or misleading statements regarding its business operations and prospects during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Telix securities from February 21, 2025, to August 28, 2025 [1][2]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - Defendants are accused of overstating progress on prostate cancer therapeutic candidates [3]. - The quality and performance of the Company's supply chain and partners were allegedly exaggerated [3]. - As a result of these misrepresentations, statements regarding the Company's business and operations were claimed to be false or misleading [3]. Group 3: Company Background - Telix Pharmaceuticals is a biopharmaceutical company based in Melbourne, Australia, focusing on radiopharmaceutical development for cancer treatment [2].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for allegedly making false statements regarding product demand and inventory levels during the specified Class Period, leading to significant stock price decline after the truth was revealed [1][3]. Company Overview - James Hardie Industries plc is a multinational building materials company based in Dublin, Ireland, specializing in fiber cement and related construction products [2]. Legal Proceedings - The lawsuit is on behalf of investors who purchased James Hardie securities between May 20, 2025, and August 18, 2025, with a deadline for potential lead plaintiff representatives set for December 23, 2025 [2][4]. - The complaint alleges that despite internal data indicating reduced inventory levels as early as April 2025, the company misled investors by claiming strong demand and normal inventory levels [3]. Financial Impact - On August 19, 2025, James Hardie disclosed a 12% decline in segment sales and warned of ongoing weakness, resulting in a stock price drop of over 34% in a single trading day [3].

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc due to allegations of financial improprieties, including a multi-year accounting scheme that concealed losses and inflated profits [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Marex shares from May 16, 2024, to August 5, 2025 [1][2]. - Investors have until December 8, 2025, to seek appointment as lead plaintiff [2]. Group 2: Allegations Against Marex - NINGI Research reported that Marex engaged in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions [3]. - The report highlighted discrepancies in intercompany receivables and loans across over 56 entities, amounting to multi-million-dollar differences [3]. - Marex allegedly concealed nearly $1 billion in off-balance-sheet derivatives, inflating operating cash flow by misclassifying structured note issuance as income [4]. Group 3: Market Reaction - Following the release of the report, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31, resulting in significant investor losses [4].

Core Points - A class action lawsuit has been filed against Jayud Global Logistics Limited on behalf of investors who acquired securities during the period from April 21, 2023, to April 30, 2025 [1][2] - The lawsuit alleges that Jayud's stock price surged from approximately $1.00 to nearly $8.00 per share due to a fraudulent "pump-and-dump" scheme, resulting in a subsequent collapse of about 95% on April 2, 2025 [3] Company Overview - Jayud Global Logistics Limited is headquartered in Shenzhen, China, and provides global cross-border supply chain solutions, including freight forwarding, supply chain management, customs brokerage, and logistics IT systems [2] Legal Context - Investors who purchased Jayud securities during the class period have until January 20, 2026, to seek appointment as lead plaintiff representatives [2] - The law firm Berger Montague, which specializes in complex civil litigation and class actions, is leading the lawsuit [4]

Core Points - A class action lawsuit has been filed against KBR, Inc. on behalf of investors who acquired shares between May 6, 2025, and June 19, 2025 [1][2] - The lawsuit alleges that KBR misled investors regarding a contract with the U.S. Department of Defense's Transportation Command, despite internal concerns about the contract [3] - Following the announcement of the contract termination on June 19, 2025, KBR's stock price dropped by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4] Company Overview - KBR, headquartered in Houston, is a global provider of science, technology, and engineering solutions for governmental and commercial clients [2] Legal Context - Investors who purchased KBR securities during the class period have until November 18, 2025, to seek appointment as lead plaintiff [2]

Core Viewpoint - A class action lawsuit has been filed against Sina Corporation, alleging that the company artificially depressed its share value during its go-private merger, impacting shareholders' ability to make informed decisions [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who sold Sina shares between October 13, 2020, and March 22, 2021, including those who sold during the go-private merger [1][2]. - Investors have until November 18, 2025, to seek appointment as lead plaintiff representatives [2]. - The lawsuit claims that critical information was withheld from proxy materials, which shareholders needed to make informed decisions [3]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants concealed the true value of Sina's investment in TuSimple, leading to a cash consideration that substantially undervalued the shares [4]. - Internal documents revealed during a related shareholder appraisal proceeding indicated that senior executives knowingly hid the investment's true value, resulting in shareholders receiving less than their shares were worth at the transaction's closing [5].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for allegedly misleading investors regarding its operations and financial performance during the specified Class Period from October 22, 2024, to October 28, 2025 [1][3]. Company Overview - Stride, Inc. is an education technology company based in Reston, Virginia, providing online learning programs, curricula, and support services to schools and districts across the United States [2]. Allegations - The lawsuit claims that Stride inflated enrollment numbers, reduced staffing below statutory limits, ignored compliance requirements, and concealed enrollment losses during the Class Period [3]. - The truth about Stride's situation was revealed on September 14, 2025, when a school district sued the company for fraud and deceptive trade practices [4]. - On October 28, 2025, Stride announced that "poor customer experience" led to increased withdrawal rates and decreased enrollments, which significantly impacted the company's stock price [4].